Today’s therapies press the accelerator. We’re building medicines to release the brake.
Engineering precision obesity medicines for better, healthier, more sustainable weight loss.
Body weight has two opposing systems
GLP-1 medicines have transformed obesity care by working the accelerator. Overture is focused on the other side of the equation.
Nutrient-stimulated hormones increase satiety, helping people eat less and lose weight.
Evolutionary biology protects fat stores by decreasing satiety and slowing energy expenditure.
Some people are born with less brake
People who naturally carry an inactive copy of a target gene are leaner and metabolically healthier. Overture aims to learn from and replicate this natural protection.
OVT-109 is Engineered to Release the Brake
- 01
Releases the Brake
Binds the native receptor and locks it in an inactive state, blocking downstream signaling.
- 02
Long-Acting Potential
Fc-engineered for half-life extension, targeting monthly-to-quarterly subcutaneous dosing.
- 03
Highly Specific
Low-nanomolar binding with no off-target hits across cell surface membrane proteome.
- 04
Complementary
Acts on orthogonal biology that can add to nutrient-stimulated hormones rather than compete with them.
A foundation for multimodal care
Obesity is biologically diverse, and many patients will be best served by more than one mechanism. OVT-109 is built as a core antibody that can stand alone, pair with incretins, or anchor long-acting multi-specifics.
All programs are investigational and have not been approved by any regulatory authority.
Expertise in antibodies and cardiometabolic disease
Randy Seeley, PhD
Scientific Advisor
Victor Garcia, PhD
Scientific Advisor
Ronenn Roubenoff, MD
Scientific Advisor
Aditya Venugopal, PhD
Board Member
Mike Schmidt, PhD
Board Member
Ron Adner
Board Member
